The Real Risks of Taking Wegovy for Weight Loss

You've just been approved. Then the nausea starts.

This is the moment most people describe in their first message to a prescriber. The nausea that arrives with Wegovy's early weeks is not a sign something has gone wrong, it is a predictable consequence of how semaglutide works. By slowing the rate at which food leaves the stomach, the medicine keeps you fuller for longer, but that same mechanism can make you feel queasy, especially after eating too quickly or too much. If you want a full picture before you begin, our guide to what the side effects of Wegovy for weight loss actually involve sets out what to expect from the first dose onwards. Most of these symptoms are dose-dependent. They tend to be at their worst when you start and again after each dose step. For the majority of people they settle within one to two weeks as the body adjusts, though some people find certain effects, particularly constipation, linger. Small, low-fat meals, eating slowly, and staying well hydrated make a practical difference. If nausea and vomiting are severe enough to prevent you keeping fluids down, that matters clinically, dehydration can put strain on the kidneys, and it is the kind of thing a prescriber needs to know about.

A pharmacist's note worth sharing: a question our prescribers hear most weeks is whether the nausea ever actually improves, or whether people are just tolerating it indefinitely. The honest answer is that genuine, sustained improvement is the norm, not the exception, but it takes longer for some than others, and pushing through a dose increase before you are ready is counterproductive. Our clinical team explores exactly this during the consultation.

When a Wegovy risk needs same-day medical attention

Serious adverse effects are uncommon, but knowing what they look like matters. Acute pancreatitis is the risk that prompted the MHRA to issue a specific Drug Safety Update for GLP-1 medicines in January 2026. The symptom to act on immediately is severe, persistent stomach pain, particularly pain that radiates through to the back, with or without vomiting. This is not the ordinary nausea of dose adjustment. It is a different quality of pain entirely, and it warrants emergency assessment that day.

Other signs that need prompt medical attention: severe right-upper-abdominal pain or pain under the ribs on the right side (possible gallbladder problems, a known association with rapid weight loss and GLP-1 use), signs of a serious allergic reaction such as throat swelling or difficulty breathing, and significant mood changes or thoughts of self-harm. Low mood as a side effect is listed in the product information and is not trivial. Tell your prescriber or GP if your mental health changes after starting treatment.

Dehydration from persistent vomiting or diarrhoea can also tip into a medical situation if fluid intake is not keeping up. Reduced urine output, dizziness on standing, and muscle cramps are signals to seek help rather than wait. The longer-term risk picture for Wegovy covers what ongoing monitoring looks like once the adjustment phase has passed.

Who carries a higher risk, and who should not take Wegovy at all

The risks of taking Wegovy for weight loss are not the same for everyone, and several groups face specific contraindications or need particular caution. Wegovy is not licensed for use during pregnancy, and Novo Nordisk's guidance (reflected in NHS patient information) is clear that it should be stopped before conception and is not appropriate while breastfeeding. Women of childbearing age using oral contraceptives alongside a GLP-1 medicine should be aware that absorption of the pill can be affected, a matter worth discussing with a prescriber before treatment starts.

A personal or family history of medullary thyroid carcinoma, or a condition called Multiple Endocrine Neoplasia type 2, rules out Wegovy because of a theoretical thyroid-tumour signal seen in animal studies. History of pancreatitis, certain kidney conditions, and active eating disorders all require careful prescriber-level assessment. The safety profile of Wegovy for weight loss covers these contraindications in more depth.

Under-18s are outside the licensed population. Wegovy is also not approved for purely cosmetic weight loss, the licensed indication covers adults with a BMI of 30 or above, or from 27 with a qualifying weight-related health condition. That threshold exists in part because the benefit-to-risk balance shifts: the greater the metabolic burden of excess weight, the clearer the clinical case for treatment. Our clinical team reviews every application individually, and no one is approved automatically.

Reporting a side effect and ongoing safety monitoring

Two things make the safety picture around Wegovy more reassuring than many people expect: the scale of post-approval surveillance and the accessibility of reporting. Wegovy carries a Black Triangle (▼) designation in the UK, meaning the MHRA actively collects additional safety data on it. Any patient, carer or healthcare professional can report a suspected side effect (including one not listed in the leaflet) via the Yellow Card scheme. The scheme exists specifically to catch signals that clinical trials may have missed, and it genuinely influences future guidance.

Ongoing prescriber review is the other layer. A responsible private prescriber does not simply dispatch repeat pens; they re-assess your weight, your response to treatment and any side effects you have experienced before each supply. If something has changed, the clinical picture needs to reflect that. The full side-effect breakdown for Wegovy gives a granular look at frequency and what the SmPC says about each one, and if you want to understand what taking Wegovy for weight loss actually feels like day to day, that page covers the practical management questions most people have. If you are weighing up Wegovy against other options, our treatment overview explains what is available and how the choices differ clinically.